MULTIPLE MYELOMA IN RELAPSE

This early-phase study is testing the safety of a new type of CAR T-cell therapy called BCMA-CD19 cCAR in patients with advanced multiple myeloma or plasmacytoid lymphoma who have no other treatment options left. The therapy uses a patient's own modified immune cells to attack ca…

This is an early-stage study to test the safety of a new type of personalized cell therapy called TriPRIL CAR T cells in adults with multiple myeloma that has come back or stopped responding to standard treatments. Researchers will first find the safest dose and then treat more p…

This early-stage trial is testing the safety of a new gene therapy called KLN-1010 for people with multiple myeloma that has returned or stopped responding to other treatments. The therapy works by modifying the patient's own immune cells inside the body to better target cancer c…

This study is testing whether a new type of cancer treatment called universal CAR-T cells is safe and effective for adults with multiple myeloma that has returned or stopped responding to other treatments. The treatment uses specially engineered immune cells from donors (not the …

This study is testing a combination of four medications to control multiple myeloma that has returned or stopped responding to prior treatments. It will involve about 43 adults whose cancer progressed after standard therapies. The main goal is to see how well this specific drug c…

This study is testing a new immune therapy called talquetamab in elderly patients whose multiple myeloma has returned after prior treatments. Talquetamab is an injection that helps the patient's own immune cells find and attack the cancer. If the cancer progresses on talquetamab …

This study is testing whether adding a new drug called inobrodib to two standard medications can help control multiple myeloma that has come back and no longer responds to available therapies. It will involve about 100 adults whose cancer has progressed despite trying several oth…

This study is testing whether adding the drug selinexor to a newer type of immunotherapy (called a bispecific antibody) is safe and more effective for people with multiple myeloma that has come back or stopped responding to other treatments. It will enroll 27 patients who have al…

This study is testing if adding early palliative (comfort) care to standard cancer treatment improves well-being for patients with multiple myeloma or aggressive lymphoma. It will involve 144 patients, and some of their caregivers, who will be randomly assigned to receive either …